1. Home
  2. MLYS vs ESQ Comparison

MLYS vs ESQ Comparison

Compare MLYS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ESQ
  • Stock Information
  • Founded
  • MLYS 2019
  • ESQ 2006
  • Country
  • MLYS United States
  • ESQ United States
  • Employees
  • MLYS N/A
  • ESQ N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ESQ Commercial Banks
  • Sector
  • MLYS Health Care
  • ESQ Finance
  • Exchange
  • MLYS Nasdaq
  • ESQ Nasdaq
  • Market Cap
  • MLYS 526.1M
  • ESQ 638.2M
  • IPO Year
  • MLYS 2023
  • ESQ 2017
  • Fundamental
  • Price
  • MLYS $10.21
  • ESQ $85.68
  • Analyst Decision
  • MLYS Strong Buy
  • ESQ Hold
  • Analyst Count
  • MLYS 2
  • ESQ 3
  • Target Price
  • MLYS $30.00
  • ESQ $88.00
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • ESQ 113.9K
  • Earning Date
  • MLYS 03-20-2025
  • ESQ 01-23-2025
  • Dividend Yield
  • MLYS N/A
  • ESQ 0.81%
  • EPS Growth
  • MLYS N/A
  • ESQ 4.68
  • EPS
  • MLYS N/A
  • ESQ 5.14
  • Revenue
  • MLYS N/A
  • ESQ $120,124,000.00
  • Revenue This Year
  • MLYS N/A
  • ESQ N/A
  • Revenue Next Year
  • MLYS N/A
  • ESQ $10.75
  • P/E Ratio
  • MLYS N/A
  • ESQ $16.70
  • Revenue Growth
  • MLYS N/A
  • ESQ 10.21
  • 52 Week Low
  • MLYS $8.58
  • ESQ $44.45
  • 52 Week High
  • MLYS $16.91
  • ESQ $90.18
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 44.53
  • ESQ 55.86
  • Support Level
  • MLYS $9.57
  • ESQ $81.10
  • Resistance Level
  • MLYS $10.79
  • ESQ $90.18
  • Average True Range (ATR)
  • MLYS 0.64
  • ESQ 2.94
  • MACD
  • MLYS 0.11
  • ESQ 0.09
  • Stochastic Oscillator
  • MLYS 63.98
  • ESQ 60.95

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. The Bank operates a payment processing platform through third-party Independent Sales Organizations.

Share on Social Networks: